This is a snippet of the transcript, sign up to read more.
Rémy was a special case during Covid because they were able to leverage their reserves and supply. The lion's share of Cognac in the US is owned by Hennessy, which covers between 60% and 70% of the market, depending on the state. The remaining 30% to 40% is made up by other Cognac suppliers, including Rémy.
This is a snippet of the transcript, sign up to read more.
Rémy managed to capture significant market share during Covid. For instance, in South Carolina, Moët Hennessy lost 10% market share, which Remy gained by providing available inventory. Due to this growth, Remy invested to ensure they had enough Cognac to supply the market demand.
This is a snippet of the transcript, sign up to read more.
However, over the last two years, Rémy has lost 30% to 40% year-over-year in the US, leading to increased inventory levels in their domestic warehouses in California and New Jersey, as well as in Belmont warehouses across 17 states.
This is a snippet of the transcript, sign up to read more.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research